C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.38 AUD 0.73% Market Closed
Market Cap: 153.4m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Wall Street
Price Targets

CYC Price Targets Summary
Cyclopharm Ltd

Wall Street analysts forecast CYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYC is 2.75 AUD with a low forecast of 2.73 AUD and a high forecast of 2.84 AUD.

Lowest
Price Target
2.73 AUD
98% Upside
Average
Price Target
2.75 AUD
100% Upside
Highest
Price Target
2.84 AUD
105% Upside
Cyclopharm Ltd Competitors:
Price Targets
SRTS
Sensus Healthcare Inc
29% Upside
LIVN
LivaNova PLC
40% Upside
DXCM
Dexcom Inc
34% Upside
AXGN
AxoGen Inc
34% Upside
PODD
Insulet Corp
7% Upside
COH
Cochlear Ltd
1% Upside
7779
Cyberdyne Inc
64% Upside
VREX
Varex Imaging Corp
36% Upside

Revenue
Forecast

Revenue Estimate
Cyclopharm Ltd

For the last 8 years the compound annual growth rate for Cyclopharm Ltd's revenue is 10%. The projected CAGR for the next 3 years is 35%.

10%
Past Growth
35%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Cyclopharm Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Net Income
Forecast

Net Income Estimate
Cyclopharm Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYC's stock price target?
Price Target
2.75 AUD

According to Wall Street analysts, the average 1-year price target for CYC is 2.75 AUD with a low forecast of 2.73 AUD and a high forecast of 2.84 AUD.

What is Cyclopharm Ltd's Revenue forecast?
Projected CAGR
35%

For the last 8 years the compound annual growth rate for Cyclopharm Ltd's revenue is 10%. The projected CAGR for the next 3 years is 35%.

Back to Top